Choosing between a mastectomy and a lumpectomy? Learn the differences in survival rates, recovery times, and common misconceptions to find the right breast cancer surgery for you.

The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...

As many as 40% of lumpectomies leave positive margins that necessitate a second surgery, but a novel fluorescent imaging agent used along with a direct visualization system may improve complete ...

Lumpectomy is the gold standard for breast cancer surgery, says Kirstyn E. Brownson, MD, a surgical breast oncologist at Huntsman Cancer Institute. We asked Dr. Brownson to explain what a lumpectomy ...

NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today ...

INSITE Trial included more than 400 patients at 14 leading academic and community cancer centers Intracavity visualization system uses fluorescence imaging designed to identify residual cancer and ...

Many patients undergoing lumpectomy surgery at NYU Langone Medical Center for the removal of an early detected breast tumor - the surgical option of choice for this diagnosis -- are benefitting from ...

For more than a decade, the number of women choosing bilateral mastectomy to treat breast cancer has been on the rise. That's the case even for women with early stage breast cancer, cancer in only one ...

And on the Beverly Hills Patch calendar - Not a house...a Lifestyle: Open Sunday 1-4 ...

Fortunately, most women treated for breast cancer will never experience a recurrence. After successfully treating the original cancer, a patient is considered “in remission.” But with breast cancer, ...

Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and ...

In this study, nearly 200 recent breast cancer survivors completed a three-month, high-intensity resistance training program.